论文部分内容阅读
通过本中心透析移植患者各３０例及３０例正常人的对照研究，表明透析组患者均有不同程度的贫血，而移植组贫血得到明显改善；分别测定三组的血促红细胞生成素（ＥＰＯ）浓度，正常人组为１２５．１９±３８．０４ｐｇ／ｍｌ，透析组为１１６．５８±３０．７５ｐｇ／ｍｌ，而移植组为１８１．０８±６４．０５ｐｇ／ｍｌ，说明终末期肾病（ＥＳＲＤ）患者与正常人相比血ＥＰＯ浓度并无明显降低，而肾移植患者血ＥＰＯ却明显升高，其贫血的改善与ＥＰＯ有关。
Through the center of dialysis transplant patients in each of 30 cases and 30 normal subjects control study showed that patients in the dialysis group have varying degrees of anemia, while the transplantation group anemia was significantly improved; were measured in three groups of blood erythropoietin (EPO) Concentration, the normal group was 125.19 ± 38.04pg / ml, the dialysis group was 116.58 ± 30.75pg / ml, while the transplantation group was 181.08 ± 64.05pg / ml, indicating that end-stage renal disease (ESRD) EPO concentration in patients with no significant reduction compared with normal blood, while renal transplant recipients of blood EPO was significantly higher, the improvement of anemia and EPO.